is compounded tirzepatide banned TGA proposes ban on injectable drugs like Ozempic and Mounjaro May 18, 2026: FDA warns

"SURPASS-CVOT will provide clinicians of people with type 2 diabetes and established cardiovascular disease with important evidence about the potential of tirzepatide to deliver outcomes beyond today's best-in-class medicines." SURPASS-CVOT (NCT04255433) includes 12,500 participants with type 2 diabetes and atherosclerotic cardiovascular disease from 30 countries

Scientific studies support using these compounds to promote hair growth, enhance skin elasticity, and support the healing process [3]

Awareness of these potential reactions allows clinicians to better counsel patients and identify medication-related skin findings when they arise

Comparison with Minoxidil Some studies have compared GHK-Cu to minoxidil, the well-known over-the-counter hair regrowth solution